Press release - 10/04/2024 Growth through medical technology: Bosch and Randox invest heavily in the Vivalytic analysis platform With its Vivalytic analysis platform, Bosch has set itself the goal of making fast and highly precise diagnostics accessible at the point of care – and aims to use molecular diagnostics to become a leading provider in the market by 2030. To achieve this, Bosch has now agreed on a strategic partnership with Randox Laboratories Ltd., a leading diagnostic and medical technology company.https://www.gesundheitsindustrie-bw.de/en/article/press-release/growth-through-medical-technology-bosch-and-randox-invest-heavily-vivalytic-analysis-platform
Press release - 16/12/2025 Hummingbird Diagnostics Publishes Study on RNA Biomarker Methylation in Liquid Biopsies Hummingbird Diagnostics GmbH, a pioneer in harnessing blood-based small RNAs for early disease detection and characterization, today announced the publication of a new study in Nature Communications Medicine introducing an Oxford Nanopore Technologies (ONT)-based method for detecting small RNA modifications in blood.https://www.gesundheitsindustrie-bw.de/en/article/hummingbird-diagnostics-publishes-study-rna-biomarker-methylation-liquid-biopsies
Press release - 25/11/2025 CELLnROLL receives funding from EXIST Research Transfer CELLnROLL is a spin-off from the Max Planck Institute for Intelligent Systems. The newly founded company develops a high-precision microrobotic-based cell sorting system to help clinicians make fast, affordable, and informed decisions for cancer diagnostics. Now, the project has received €865,000 in funding through the EXIST Transfer of Research program, a funding program initiated by the German Federal Ministry for Economic Affairs and Energy. https://www.gesundheitsindustrie-bw.de/en/article/press-release/cellnroll-receives-funding-exist-research-transfer
Dossier - 08/09/2022 Imaging methods in medical diagnostics Many different imaging methods are available these days and are used in almost all medical disciplines to visualise disease-related changes. Depending on the problem and the clinical picture, very different structural and functional parameters can be visually recorded for diagnosis and used for therapy.https://www.gesundheitsindustrie-bw.de/en/article/dossier/imaging-methods-medical-diagnostics
Press release - 17/01/2024 AI-based support system for skin cancer diagnostics explains its decisions Artificial intelligence (AI) can help dermatologists to detect skin cancer. However, many dermatologists distrust the algorithms' decisions, which they cannot comprehend. Scientists at the German Cancer Research Center have now developed an AI-based support system for skin cancer diagnostics that explains its decisions.https://www.gesundheitsindustrie-bw.de/en/article/press-release/ai-based-support-system-skin-cancer-diagnostics-explains-its-decisions
Company profile: medicalvalues GmbH - 05/05/2022 medicalvalues – best possible diagnostics thanks to AI The Karlsruhe-based start-up medicalvalues GmbH wants to use its platform to bring together different clinical data sets and thus enable comprehensive medical diagnostics. Artificial intelligence featuring innovative diagnostic algorithms is used to evaluate the data and generate new insights for laboratories and hospitals.https://www.gesundheitsindustrie-bw.de/en/article/news/medicalvalues-best-possible-diagnostics-thanks-ai
Press release - 18/04/2024 Additional partnership in medical technology: Bosch and R-Biopharm to strengthen Vivalytic analysis platform The market for medical technology is innovative, dynamic, and growing. Bosch sees medical technology as a strategic growth field and intends to expand its Bosch Healthcare Solutions subsidiary, based in Waiblingen. Bosch has now entered into a new partnership with the German diagnostics solutions company R-Biopharm. This partnership will be focused on Bosch’s universal, fully automated Vivalytic molecular diagnostic analysis platform. https://www.gesundheitsindustrie-bw.de/en/article/press-release/additional-partnership-medical-technology-bosch-and-r-biopharm-strengthen-vivalytic-analysis-platform
Press release - 12/06/2024 Pathogen identification — next-generation sequencing optimizes diagnostics Invasive infections such as sepsis require immediate and targeted treatment. Experts from the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB and group partners have succeeded in establishing a reconceptualized detection principle that can make a crucial contribution to saving lives through fast, ultra-accurate pathogen identification. They have been chosen to receive the 2024 Stifterverband Science Prize for their efforts.https://www.gesundheitsindustrie-bw.de/en/article/press-release/pathogen-identification-next-generation-sequencing-optimizes-diagnostics
Press release - 02/07/2024 DKFZ spin-off Epignostix raises €4.3m seed round to commercialize diagnostic tumor classifier Heidelberg Epignostix GmbH, a deeptech start-up committed to precision cancer diagnostics today announces €4.3M in seed funding. This investment will enable Heidelberg Epignostix to make a substantial leap forward in driving market development for its flagship indication for brain tumor classification.https://www.gesundheitsindustrie-bw.de/en/article/press-release/dkfz-spin-epignostix-raises-euro-43m-seed-round-commercialize-diagnostic-tumor-classifier
Dossier - 10/03/2014 Cancer therapy and cancer diagnostics Thanks to improved diagnostics and therapy, today’s cancer patients can live considerably longer than patients several years ago. Nevertheless, some cancers, especially the strongly metastatic ones, are difficult to treat. Therapies targeting immune cells or cancer stem cells could potentially improve the current situation. https://www.gesundheitsindustrie-bw.de/en/article/dossier/cancer-therapy-and-cancer-diagnostics
Dossier - 26/11/2012 Genetic diagnostics technology reaches the limits of what is medically reasonable Rapid progress in sequencing technologies is poised to set the imagination of biomedical researchers on fire. Experts now believe that progress is about to make possible what seemed to be utopian a few years ago – it seems likely that it will soon be possible to sequence the human genome in only a few minutes and store and automatically analyse it using tiny automates. However, is everything that is technically feasible also reasonable?https://www.gesundheitsindustrie-bw.de/en/article/dossier/genetic-diagnostics-technology-reaches-the-limits-of-what-is-medically-reasonable
Press release - 15/10/2025 NGS-based diagnostics for identifying sepsis pathogens wins EARTO Innovation Award A method developed at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB enables bacterial, viral, fungal, or parasitic pathogens in sepsis patients to be identified much faster than before and with the highest precision. The approach is based on high-throughput sequencing of cell-free DNA circulating in the blood and was honored with the EARTO Innovation Award in the "Impact Delivered" category on October 14,…https://www.gesundheitsindustrie-bw.de/en/article/press-release/ngs-based-diagnostics-identifying-sepsis-pathogens-wins-earto-innovation-award
Dossier - 04/11/2013 Biotechnology driver of innovation in the pharmaceutical industry The biotech industry is the innovative driver for a pharmaceutical industry that, due to the shift from blockbluster products to personalised medicine, now depends on new concepts. The production of new drugs using genetic engineering relies on knowledge gained from genomics, proteomics and systems biology and creates new treatment strategies that combine therapy and diagnostics (i.e. companion diagnostics) to provide a specific individualised…https://www.gesundheitsindustrie-bw.de/en/article/dossier/biotechnology-driver-of-innovation-in-the-pharmaceutical-industry
Press release - 13/05/2024 Detecting respiratory infections: simply blow for diagnosis Professor Claudia Denkinger from Heidelberg University's Faculty of Medicine is leading the international collaborative project "BreathForDiagnosis". Researchers from Germany, Italy, South Africa and Romania are working with an industrial partner from Switzerland to develop user-friendly breath tests for the rapid diagnosis of respiratory infections such as tuberculosis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/detecting-respiratory-infections-simply-blow-diagnosis
Press release - 06/02/2026 nanodiag BW receives funding for second implementation phase nanodiag BW has received approval from the BMFTR for a further three-year implementation phase under the Clusters4Future initiative. With the approval of €15 million, the innovation network will be able to continue its work on nanopore-based diagnostic methods seamlessly from April 2026 onwards. The Baden-Württemberg Ministry of Economic Affairs, Labour and Tourism is supporting the cluster management through accompanying measures.https://www.gesundheitsindustrie-bw.de/en/article/press-release/nanodiag-bw-receives-funding-second-implementation-phase
Press release - 10/04/2024 Cyber Valley grants 500K to CELL’n’ROLL via 2023 Innovation Fellowship Program Pioneering cutting-edge diagnostic systems for the detection of complex diseases: Cyber Valley is pleased to announce it has awarded funding of 500K EUR to the CELL’n’ROLL team through the 2023 Cyber Valley Innovation Fellowship program, funded by the Carl-Zeiss-Stiftung.https://www.gesundheitsindustrie-bw.de/en/article/press-release/cyber-valley-grants-500k-cellnroll-2023-innovation-fellowship-program
Article - 10/03/2021 Faster to single cells using miniature grinder Tissue cells are needed for medical diagnostics, cell therapies and tissue engineering, among other things. A novel tissue grinder gently and automatically dissociates cells from tissue. In November 2020, the newly founded biotech company Fast Forward Discoveries GmbH (FFX) delivered its first tissue grinders to customers.https://www.gesundheitsindustrie-bw.de/en/article/news/faster-single-cells-using-miniature-grinder
Press release - 26/05/2025 Explainable artificial intelligence increases the accuracy and endurance of dermatologists in melanoma diagnosis Scientists at the German Cancer Research Center (DKFZ) have shown in an international eye-tracking study that dermatologists not only improve their diagnostic accuracy by using explainable artificial intelligence, but also show significantly less fatigue when assessing challenging cases. The researchers were able to demonstrate this by measuring a reduction in cognitive stress indicators.https://www.gesundheitsindustrie-bw.de/en/article/press-release/explainable-artificial-intelligence-increases-accuracy-and-endurance-dermatologists-melanoma-diagnosis
Press release - 16/07/2021 Corona test with cotton swab To diagnose an infection with the coronavirus, usually a throat swab is taken and genetic viral material detected by using a highly sensitive PCR. To date, more than 65 million of these tests have been performed in Germany alone. Due to the massive increase in testing worldwide and simultaneous loss of production, there was a significant shortage of test materials in the early stage of the pandemic.https://www.gesundheitsindustrie-bw.de/en/article/press-release/corona-test-cotton-swab
Event - 07/10/2025 - 08/10/2025 Diagnostics-4-Future Conference 2025 Konstanz, Germany , Kongress/Symposium https://www.gesundheitsindustrie-bw.de/en/event/diagnostics-4-future-conference-2025
Press release - 14/03/2024 Planned NMI spin-off: immuneAdvice successful in start-up competition Does our therapeutic approach work against cancer? The answer to this question can make the difference between life and death - and is still difficult to answer. A team from the NMI Natural and Medical Sciences Institute at the University of Tübingen and the Werner Siemens Imaging Center Tübingen has developed a technique for observing immune cells. https://www.gesundheitsindustrie-bw.de/en/article/press-release/geplante-nmi-ausgruendung-immuneadvice-bei-startup-wettbewerb-erfolgreich
UKCA product marking - 18/12/2024 New medical device marking requirements and regulations in Great Britain Since Brexit, additional regulations for medical devices have come into effect in Great Britain, i.e. England, Wales and Scotland. Although the transition periods have been extended, medical device manufacturers should familiarise themselves with the new conformity marking requirements. EU medical device regulations will continue to apply in Northern Ireland.https://www.gesundheitsindustrie-bw.de/en/article/news/new-medical-device-marking-requirements-and-regulations-great-britain
Press release - 31/01/2023 ERC Consolidator Grants for Two Researchers from KIT In the 2022 allocation round for the award of the prestigious Consolidator Grants of the European Research Council, researchers of Karlsruhe Institute of Technology (KIT) have been successful. For their projects in the fields of photovoltaics and medical sensor technology, physicist Ulrich W. Paetzold and chemist Frank Biedermann will receive approximately two million euros over the next five years.https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-consolidator-grants-fuer-zwei-forscher-des-kit
Press release - 17/02/2026 Tracing Tumors in Cerebrospinal Fluid: A New Opportunity for Precision Diagnostics in Brain Tumors In a published scientific study, researchers have succeeded in accurately diagnosing common types of brain tumors in children and adolescents based on tumor-derived genetic material in cerebrospinal fluid. Until now, these so-called liquid biopsies were not capable enough for such reliable diagnostics. The international research team has therefore optimized a sequencing technique and developed an AI-based computational method. In a later step,…https://www.gesundheitsindustrie-bw.de/en/article/press-release/tracing-tumors-cerebrospinal-fluid-new-opportunity-precision-diagnostics-brain-tumors